<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-713" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Benazepril</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dahal</surname>
            <given-names>Sujata S.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sujata Dahal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-713.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Benazepril is an angiotensin-converting enzyme (ACE) inhibitor prescribed for&#x000a0;hypertension management. Hypertension is a significant risk factor for cardiovascular morbidity and requires effective control. Understanding the FDA-approved indications, mechanism of action, and contraindications&#x000a0;for benazepril is essential for healthcare professionals. Providers must also be aware of&#x000a0;its adverse event profile, dosing, pharmacodynamics, pharmacokinetics, and monitoring requirements. Awareness of relevant drug-drug interactions, especially in patients with renal impairment or specific populations, enhances patient safety. Interprofessional collaboration among healthcare team members optimizes therapeutic outcomes when prescribing benazepril. Providing detailed information on benazepril supports the effective management of patients with hypertension and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for initiating&#x000a0;benazepril therapy.</p></list-item><list-item><p>Determine benazepril's mechanism of action.</p></list-item><list-item><p>Identify the potential side effects&#x000a0;associated with benazepril therapy.</p></list-item><list-item><p>Implement&#x000a0;interprofessional team strategies for improving coordination and communication to improve outcomes for patients receiving benazepril therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=713&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=713">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-713.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Benazepril hydrochloride is approved by the United States Food and Drug Administration for the treatment of hypertension, either&#x000a0;as monotherapy or in combination with other antihypertensive agents.<xref ref-type="bibr" rid="article-713.r1">[1]</xref>&#x000a0;Benazepril reduces blood pressure and, subsequently, the risk of&#x000a0;significant cardiovascular events such as myocardial infarctions and strokes.</p>
        <p>Benazepril may be co-administered with thiazide diuretics and calcium channel blockers. According to the American College of Cardiology/American Heart Association (ACC/AHA) 2017 Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in adults, upon suboptimal response to initial monotherapy or where combination therapy is needed to lower blood pressure by at least 20/10 mm Hg, benazepril may be&#x000a0;administered with another appropriate agent (eg, thiazide diuretics or long-acting dihydropyridine calcium channel blockers).<xref ref-type="bibr" rid="article-713.r2">[2]</xref></p>
      </sec>
      <sec id="article-713.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Reduction of Blood Pressure</bold>
</p>
        <p>Angiotensin-converting enzyme (ACE) plays a critical role in the renin-angiotensin-aldosterone system. This pathway eventually results in vasoconstriction, increased sympathetic activity, and sodium (Na<sup>+</sup>) retention, increasing water retention and blood pressure. One step in this pathway is the&#x000a0;conversion of angiotensin I to angiotensin II, performed by ACE. ACE inhibitors&#x000a0;suppress&#x000a0;the renin-angiotensin pathway by halting this step, causing a reduction in systemic arterial blood pressure and increased urinary Na<sup>+</sup> excretion.&#x000a0;</p>
        <p>ACE inhibitors also&#x000a0;suppress bradykinin metabolism. Bradykinin is a natural vasodilator usually degraded by ACE into inactive metabolites. However, this vasodilator's effect is preserved when the ACE enzyme is inhibited, reducing blood pressure.<xref ref-type="bibr" rid="article-713.r3">[3]</xref></p>
        <p>
<bold>Reduced&#x000a0;Cardiac Remodeling</bold>
</p>
        <p>In patients with heart failure, the renin-angiotensin-aldosterone system (RAAS) becomes active due to low cardiac output, leading to reduced renal artery perfusion. Renal hypoperfusion&#x000a0;triggers the RAAS pathway to increase intravascular volume and blood pressure, which increases cardiac output via the Frank-Starling mechanism. However, this attempt at maintaining homeostasis ultimately results in increased&#x000a0;cardiac preload, contributing to adverse remodeling of the heart's structure. This cascade can&#x000a0;cause eccentric hypertrophy, which becomes detrimental quickly. Patients who adhere to a low-potassium diet and a strict&#x000a0;ACE inhibitor&#x000a0;regimen while&#x000a0;regularly monitoring blood pressure and renal function should expect significant reductions&#x000a0;in blood pressure and adverse cardiac remodeling.<xref ref-type="bibr" rid="article-713.r3">[3]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Benazepril's pharmacokinetics are dose-proportional within the 10 to 80 mg dosage range. Benazepril's active metabolite is benazeprilat. After oral benazepril administration, peak plasma concentrations of benazepril are typically reached within 1 hour, and benazeprilat within 1 to 2 hours. While benazepril's bioavailability is not affected by food, the time to reach peak plasma concentration of benazeprilat is delayed (up to 4 hours) if taken with meals.</p>
        <p><bold>Distribution:&#x000a0;</bold>Benazepril and benazeprilat&#x000a0;are highly protein-bound (96.7% and 95.3%, respectively).</p>
        <p><bold>Metabolism:&#x000a0;</bold>Benazepril is almost completely metabolized primarily in the liver to benazeprilat.&#x000a0;The effective half-life of benazeprilat after daily oral dosing of benazepril hydrochloride is approximately 10 to 11 hours. Steady-state levels of benazeprilat are typically achieved after administering 2 or 3 doses of benazepril hydrochloride once daily.</p>
        <p><bold>Elimination:&#x000a0;</bold>Benazepril and benazeprilat are eliminated predominantly by renal excretion.</p>
      </sec>
      <sec id="article-713.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Available Dosage Forms and Strengths</bold>&#x000a0;</p>
        <p>Benazepril is available&#x000a0;in 5 mg, 10 mg, 20 mg, and 40 mg oral tablets.&#x000a0;The drug should be taken once or twice a day at consistent times and&#x000a0;may be taken with or without food.<xref ref-type="bibr" rid="article-713.r4">[4]</xref>&#x000a0;Doses taken in the&#x000a0;morning&#x000a0;have&#x000a0;a more prolonged effectiveness (~19 hours) than those taken in the afternoon.&#x000a0;No data is available for daily doses exceeding&#x000a0;80 mg.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The recommended starting dosage is 10 mg once daily. Maintenance dosages range from 20 to 40 mg daily. Benazepril should be taken once or twice a day at consistent times.<xref ref-type="bibr" rid="article-713.r4">[4]</xref>&#x000a0;Dosage adjustments should be&#x000a0;based on peak (2&#x000a0;to 6 hours after dosing) and trough responses. If once-daily dosing does not&#x000a0;result in a satisfactory&#x000a0;trough response, an increase in dosage or divided administration should be considered. A diuretic can be added if benazepril&#x000a0;monotherapy does not effectively control blood pressure. When patients are&#x000a0;also receiving&#x000a0;diuretics, the recommended starting dose of benazepril is 5 mg to avoid excessive hypotension.<xref ref-type="bibr" rid="article-713.r5">[5]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The recommended starting dose is 5 mg once daily for patients with renal impairment (CrCl &#x0003c;30 mL/min). The dose is increased&#x000a0;incrementally to achieve the desired blood pressure, and the maximum daily dose should not exceed 40 mg.<xref ref-type="bibr" rid="article-713.r4">[4]</xref></p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;ACE inhibitors should be avoided in patients with cirrhosis and ascites, as their&#x000a0;administration may further reduce renal blood flow and potentially trigger hepatorenal syndrome.<xref ref-type="bibr" rid="article-713.r6">[6]</xref><xref ref-type="bibr" rid="article-713.r7">[7]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;ACE inhibitors (including benazepril) are contraindicated in pregnancy, as their administration can result in fetal teratogenicity and death. Benazepril therapy during the second and third trimesters is associated with&#x000a0;fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, renal failure, and death. Infants who have been exposed to benazepril in utero should be closely monitored for hypotension, oliguria, and hyperkalemia.<xref ref-type="bibr" rid="article-713.r1">[1]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Minimal amounts of benazepril and its metabolites&#x000a0;have been detected in the&#x000a0;breast milk of lactating women&#x000a0;receiving&#x000a0;benazepril. Maternal benazepril use is not associated with any adverse effects in breastfed&#x000a0;infants.<xref ref-type="bibr" rid="article-713.r8">[8]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The recommended starting dose is 0.2 mg/kg once daily, and the maintenance dose ranges from 0.1 to 0.6 mg/kg once daily. Benazepril should be taken once daily at consistent times.<xref ref-type="bibr" rid="article-713.r4">[4]</xref>&#x000a0;Benazepril administration has not been&#x000a0;studied in children&#x000a0;younger than 6.</p>
        <p><bold>Older patients:</bold>&#x000a0;Clinicians should consider a starting dose of less than 10 mg once daily to minimize any adverse drug reactions that may occur.<xref ref-type="bibr" rid="article-713.r9">[9]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/benazepril-drug-information/abstract-text/2645758/pubmed"/></p>
      </sec>
      <sec id="article-713.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The following adverse&#x000a0;drug reactions have been associated with benazepril administration.</p>
        <p><bold>Cough</bold>&#x000a0;</p>
        <p>The mechanism of action that causes a dry cough in patients taking ACE inhibitors is related to reduced bradykinin degradation. Bradykinin is a known mediator of blood pressure in the upper respiratory tract, and it can cause cough if elevated levels are present. ACE inhibitor-induced dry cough incidence ranges from&#x000a0;5% to 35%.<xref ref-type="bibr" rid="article-713.r3">[3]</xref><xref ref-type="bibr" rid="article-713.r10">[10]</xref><xref ref-type="bibr" rid="article-713.r11">[11]</xref></p>
        <p>
<bold>Hypotension</bold>
</p>
        <p>Benazepril has been rarely associated with hypotension in patients with&#x000a0;uncomplicated hypertension. Significant hypotension is most likely to occur in patients who are volume&#x000a0;and salt-depleted due to diuretic therapy, salt restriction, dialysis, diarrhea, or vomiting. Volume and salt depletion should be corrected before initiating or resuming benzapril therapy.<xref ref-type="bibr" rid="article-713.r1">[1]</xref><xref ref-type="bibr" rid="article-713.r3">[3]</xref></p>
        <p><bold>Renal Insufficiency</bold>&#x000a0;</p>
        <p>Hypotension leading to&#x000a0;reduced&#x000a0;renal perfusion can occur in patients with volume depletion and can cause permanent renal impairment.&#x000a0;Clinicians should ensure euvolemia and reduce the dosage of the ACE inhibitor, if necessary. Furthermore, initiating ACE inhibitor therapy can precipitate renal failure due to the reduction of glomerular hydrostatic pressure in patients&#x000a0;with bilateral renal artery stenosis.<xref ref-type="bibr" rid="article-713.r1">[1]</xref></p>
        <p>
<bold>Hyperkalemia&#x000a0;</bold>
</p>
        <p>ACE inhibitors reduce the serum aldosterone concentration,&#x000a0;which&#x000a0;can increase the serum concentration of potassium. Patients with renal insufficiency or diabetes or who are receiving diuretic therapy are at high risk of developing hyperkalemia.<xref ref-type="bibr" rid="article-713.r3">[3]</xref>&#x000a0;Clinicians should consider&#x000a0;reducing doses of diuretics, lithium, and potassium and carefully monitoring for adverse drug reactions. Frequent monitoring of serum lithium levels is recommended when the patient is also&#x000a0;receiving&#x000a0;lithium. If a diuretic is co-administered, the risk of lithium toxicity may be increased.<xref ref-type="bibr" rid="article-713.r4">[4]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p><bold>Diuretics:</bold> Co-administration of diuretics and benazepril can result in excessively low blood pressure, especially&#x000a0;during the initiation of benazepril therapy. This risk can be mitigated by discontinuing or&#x000a0;reducing the diuretic dose before starting benazepril therapy. Potassium-sparing diuretics (eg, amiloride, spironolactone, triamterene) increase the risk of hyperkalemia when co-administered with benazepril. Clinicians must monitor the patient's serum potassium levels when the combination can not be avoided.</p>
        <p><bold>Diabetes medications:</bold> Insulin and oral hypoglycemic agents increase the potential for hypoglycemia when co-administered with benazepril.</p>
        <p><bold>NSAIDs&#x000a0;(selective COX-2 inhibitors):</bold>&#x000a0;Co-administration of nonsteroidal anti-inflammatory agents&#x000a0;and benazepril can result in significantly reduced renal function (and potentially acute renal failure) in patients who are volume-depleted (eg,&#x000a0;receiving&#x000a0;diuretic therapy) or older or&#x000a0;who have impaired renal function. Clinicians should monitor renal function periodically in these patients. Furthermore, nonsteroidal anti-inflammatory drugs can reduce the antihypertensive efficacy of ACE inhibitors (including benazepril).</p>
        <p><bold>Renin-angiotensin system inhibition:</bold>&#x000a0;Dual blockade of the renin-angiotensin system (RAS) with ACE inhibitors, angiotensin II receptor blockers (ARBs), or aliskiren&#x000a0;is associated with increased risks of hyperkalemia, hypotension, and&#x000a0;reduced&#x000a0;renal&#x000a0;function compared to monotherapy. These combinations should be avoided, if possible. Clinicians prescribing agents that cause dual blockade of RAS should monitor the patient's blood&#x000a0;pressure, electrolytes, and renal function.</p>
        <list list-type="bullet">
          <list-item>
            <p>Do not co-administer aliskiren&#x000a0;and benazepril&#x000a0;to patients with diabetes.</p>
          </list-item>
          <list-item>
            <p>Avoid the use of&#x000a0;aliskiren with benazepril in patients with renal impairment (CrCL &#x0003c;60&#x000a0;mL/min).</p>
          </list-item>
        </list>
        <p><bold>Rapamycin-related medications:</bold>&#x000a0;Co-administration of an ACE inhibitor and a mammalian target of rapamycin&#x000a0;inhibitor (eg, sirolimus, everolimus, temsirolimus) can increase the risk&#x000a0;of angioedema.&#x000a0;</p>
        <p><bold>Lithium:</bold>&#x000a0;Lithium&#x000a0;toxicity&#x000a0;has been reported&#x000a0;in&#x000a0;patients&#x000a0;receiving benazepril and&#x000a0;lithium&#x000a0;concomitantly. Although toxicity is reversible upon discontinuation of benazepril or lithium,&#x000a0;clinicians should monitor serum lithium levels in patients receiving this combination.</p>
        <p><bold>Neprilysin inhibitors:</bold> The co-administration of neprilysin inhibitors and benazepril may increase the risk of angioedema.</p>
      </sec>
      <sec id="article-713.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Benazepril should not be administered in the following situations:</p>
        <list list-type="bullet">
          <list-item>
            <p>The&#x000a0;patient has&#x000a0;a history of hypersensitivity to benazepril or other ACE inhibitors&#x000a0;<xref ref-type="bibr" rid="article-713.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The&#x000a0;patient has a history of angioedema or a history of angioedema caused by ACE inhibitors&#x000a0;<xref ref-type="bibr" rid="article-713.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>The patient has received valsartan or sacubitril within the last 36 hours&#x000a0;<xref ref-type="bibr" rid="article-713.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The&#x000a0;patient has diabetes and is being treated with aliskiren&#x000a0;<xref ref-type="bibr" rid="article-713.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Boxed Warning</bold>
</p>
        <p><bold>Fetal/neonatal morbidity and mortality:&#x000a0;</bold>When used during the second and third trimesters of pregnancy, ACE inhibitors can cause injury and even death to the developing fetus. Upon detection of&#x000a0;pregnancy, discontinue the use of benazepril as soon as possible.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Head and neck angioedema:</bold>&#x000a0;During&#x000a0;clinical trials, 0.5% of patients experienced angioedema while&#x000a0;receiving&#x000a0;benazepril. Angioedema involves the face, tongue, glottis, or larynx and can progress to airway obstruction. Benazepril should be discontinued if the patient develops angioedema.<xref ref-type="bibr" rid="article-713.r12">[12]</xref></p>
        <p><bold>Intestinal angioedema:</bold>&#x000a0;Patients presenting with abdominal pain&#x000a0;should be suspected&#x000a0;of intestinal angioedema. In some patients, abdominal pain can present along with nausea and vomiting. An abdominal CT scan or ultrasound is necessary to rule out intestinal angioedema.<xref ref-type="bibr" rid="article-713.r12">[12]</xref></p>
        <p><bold>Hepatic failure:</bold>&#x000a0;ACE inhibitors can rarely cause hepatic failure. This process begins with cholestatic jaundice and progresses to fulminant hepatic necrosis&#x000a0;and potentially death. Patients&#x000a0;receiving ACE inhibitors who develop jaundice or hepatic enzyme elevations should discontinue ACE inhibitors and be monitored closely for signs of hepatic failure.<xref ref-type="bibr" rid="article-713.r13">[13]</xref></p>
        <p><bold>Neutropenia/agranulocytosis:</bold>&#x000a0;ACE inhibitors can induce agranulocytosis and bone marrow suppression in patients with renal impairment and systemic lupus erythematosus. If a patient is known to have a collagen-vascular disease associated with reduced renal function, then white blood cell counts should be monitored closely.<xref ref-type="bibr" rid="article-713.r14">[14]</xref></p>
        <p><bold>Hepatic failure:</bold> ACE inhibitors&#x000a0;are associated with&#x000a0;cholestatic jaundice,&#x000a0;severe hepatic necrosis, and, in some cases, death. The exact mechanism behind this syndrome is unclear. Patients&#x000a0;who experience jaundice or significant&#x000a0;elevations in liver enzymes while receiving ACE inhibitors should stop&#x000a0;taking the medication and seek appropriate medical evaluation.</p>
      </sec>
      <sec id="article-713.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient&#x02019;s blood pressure requires daily monitoring to determine proper maintenance dosages. Benazepril efficacy diminishes after 12 to 19 hours, so blood pressure monitoring should be planned accordingly.<xref ref-type="bibr" rid="article-713.r4">[4]</xref>&#x000a0;Renal function is monitored by regularly obtaining serum creatinine,&#x000a0;blood urea nitrogen, and potassium levels.&#x000a0;For patients with renal dysfunction, establishing baseline kidney function should take place before treatment and afterward at 2-week intervals for&#x000a0;3 months.<xref ref-type="bibr" rid="article-713.r15">[15]</xref><xref ref-type="bibr" rid="article-713.r16">[16]</xref></p>
      </sec>
      <sec id="article-713.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are no reports of renal failure in patients taking benazepril. The frequency of neutropenia and proteinuria&#x000a0;were statistically insignificant compared to placebo during clinical trials. Compared to other ACE inhibitors, benazepril demonstrated a reduced rate of inducing systematic hypotension and the same rate of causing adverse drug reactions such as coughing, hyperkalemia, and serum creatinine elevation.<xref ref-type="bibr" rid="article-713.r17">[17]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>If benazepril ingestion is recent, clinicians can consider treatment with activated charcoal. Meanwhile, gastric decontamination (eg, vomiting, gastric lavage) should be considered if ingestion is recent.</p>
          </list-item>
          <list-item>
            <p>The patient's clinical symptoms and blood pressure should be closely monitored. Supportive management should be used to maintain systemic blood pressure and ensure adequate hydration.</p>
          </list-item>
          <list-item>
            <p>For patients with marked hypotension, the recommendation is to infuse physiological saline solution and, as needed, consider treatment with vasopressors (eg, intravenous catecholamines).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-713.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Increased systolic and diastolic blood pressure heightens cardiovascular risk, with the rise in absolute risk being more pronounced at higher blood pressure levels. Therefore, even slight decreases in blood pressure can yield significant benefits. While the relative risk reduction from lowering blood pressure remains consistent across different populations, the absolute benefits are more substantial for patients at higher risk, such as those with diabetes or hyperlipidemia. These patients likely benefit from more aggressive treatment to achieve lower blood pressure targets. Certain antihypertensive medications may have less pronounced effects on blood pressure when used as monotherapy in Black patients.</p>
        <p>Many antihypertensive drugs have other approved uses and benefits, such as managing angina, heart failure, or diabetic kidney disease. These factors help a clinician navigate therapy choices. Prescribers starting patients on benazepril for any indicated use should coordinate efforts with other interprofessional healthcare team members, including clinicians, mid-level practitioners, pharmacists, and nursing staff. Pharmacists should check for appropriate dosing, potential drug interactions, and contraindications. Nurses should assist with regular blood pressure checkups, ensure proper drug administration, and report abnormalities to the team. An interprofessional team approach is necessary when administering any medication, and benazepril is no exception; this increases the chances of therapeutic success and minimizes adverse drug reactions.</p>
      </sec>
      <sec id="article-713.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=713&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=713">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/713/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=713">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-713.s11">
        <title>References</title>
        <ref id="article-713.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.</article-title>
            <source>Drugs</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>511</fpage>
            <page-range>511-39</page-range>
            <pub-id pub-id-type="pmid">1720384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Herman</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Angiotensin-Converting Enzyme Inhibitors (ACEI)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">28613705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bicket</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Using ACE inhibitors appropriately.</article-title>
            <source>Am Fam Physician</source>
            <year>2002</year>
            <month>Aug</month>
            <day>01</day>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>461</fpage>
            <page-range>461-8</page-range>
            <pub-id pub-id-type="pmid">12182524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palatini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Motolese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mormino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Torre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varotto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pavan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pessina</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Effect of evening versus morning benazepril on 24-hour blood pressure: a comparative study with continuous intraarterial monitoring.</article-title>
            <source>Int J Clin Pharmacol Ther Toxicol</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>295</fpage>
            <page-range>295-300</page-range>
            <pub-id pub-id-type="pmid">8335427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biggins</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gin&#x000e8;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Nadim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>1014</fpage>
            <page-range>1014-1048</page-range>
            <pub-id pub-id-type="pmid">33942342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaiser</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ackermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sioufi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations.</article-title>
            <source>Am Heart J</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>746</fpage>
            <page-range>746-51</page-range>
            <pub-id pub-id-type="pmid">2919553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Benazepril</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitors in the elderly.</article-title>
            <source>Am Heart J</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>751</fpage>
            <page-range>751-5</page-range>
            <pub-id pub-id-type="pmid">2645758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dicpinigaitis</surname>
                <given-names>PV</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>129</volume>
            <issue>1 Suppl</issue>
            <fpage>169S</fpage>
            <page-range>169S-173S</page-range>
            <pub-id pub-id-type="pmid">16428706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hou</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of benazepril for advanced chronic renal insufficiency.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>12</day>
            <volume>354</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-40</page-range>
            <pub-id pub-id-type="pmid">16407508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bezalel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahlab-Guri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sthoeger</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor-induced angioedema.</article-title>
            <source>Am J Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>128</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-5</page-range>
            <pub-id pub-id-type="pmid">25058867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeserich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ihling</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allgaier</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Heilmann</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acute liver failure due to enalapril.</article-title>
            <source>Herz</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>689</fpage>
            <page-range>689-93</page-range>
            <pub-id pub-id-type="pmid">11141678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashmi</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Khaja</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Benazepril-Induced Agranulocytosis: A Case Report and Review of the Literature.</article-title>
            <source>Am J Case Rep</source>
            <year>2016</year>
            <month>Jun</month>
            <day>23</day>
            <volume>17</volume>
            <fpage>425</fpage>
            <page-range>425-8</page-range>
            <pub-id pub-id-type="pmid">27335175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moffett</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Denfield</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Knudson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">24233240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mansfield</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Bhaskaran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nitsch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Smeeth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study.</article-title>
            <source>BMJ Open</source>
            <year>2017</year>
            <month>Jan</month>
            <day>09</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>e012818</fpage>
            <pub-id pub-id-type="pmid">28069618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-713.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacNab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mallows</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of benazepril in essential hypertension.</article-title>
            <source>Clin Cardiol</source>
            <year>1991</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8 Suppl 4</issue>
            <fpage>IV33</fpage>
            <page-range>IV33-7; discussion IV51-5</page-range>
            <pub-id pub-id-type="pmid">1893640</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
